COMMONWEALTH EQUITY SERVICES, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.

Quarter-by-quarter ownership
COMMONWEALTH EQUITY SERVICES, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$619
+8.2%
16,216
+2.2%
0.00%0.0%
Q2 2023$572
-2.1%
15,869
+3.6%
0.00%0.0%
Q1 2023$584
-54.2%
15,318
-31.7%
0.00%
-66.7%
Q4 2022$1,275
-99.9%
22,425
-17.9%
0.00%0.0%
Q3 2022$1,080,000
-9.9%
27,322
+0.2%
0.00%0.0%
Q2 2022$1,199,000
+54.3%
27,271
+39.9%
0.00%
+50.0%
Q1 2022$777,000
-0.8%
19,4940.0%0.00%0.0%
Q4 2021$783,000
+5.1%
19,494
+6.4%
0.00%0.0%
Q3 2021$745,000
-13.4%
18,324
-3.3%
0.00%0.0%
Q2 2021$860,000
-6.7%
18,958
-14.3%
0.00%
-33.3%
Q1 2021$922,000
-1.9%
22,128
+0.4%
0.00%0.0%
Q4 2020$940,000
+21.4%
22,032
-25.3%
0.00%0.0%
Q3 2020$774,000
-2.1%
29,485
-0.2%
0.00%0.0%
Q2 2020$791,000
+39.5%
29,535
-6.3%
0.00%0.0%
Q1 2020$567,000
+1.1%
31,535
-0.5%
0.00%
+50.0%
Q4 2019$561,000
-19.4%
31,695
-29.4%
0.00%
-33.3%
Q3 2019$696,000
-9.7%
44,8900.0%0.00%0.0%
Q2 2019$771,000
+9.4%
44,890
+2.4%
0.00%0.0%
Q1 2019$705,000
+10.3%
43,840
+0.3%
0.00%0.0%
Q4 2018$639,000
-80.6%
43,730
-75.9%
0.00%
-81.2%
Q3 2018$3,290,000
+79.2%
181,108
+66.4%
0.02%
+60.0%
Q2 2018$1,836,000
-12.2%
108,829
+2.0%
0.01%
-9.1%
Q1 2018$2,090,0000.0%106,729
+3.4%
0.01%0.0%
Q4 2017$2,090,000103,1760.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Third Security, LLC 19,305,403$233,209,00010.86%
BB BIOTECH AG 7,379,832$89,148,0003.13%
SENZAR ASSET MANAGEMENT, LLC 550,544$6,650,572,0001.72%
SNYDER CAPITAL MANAGEMENT L P 2,232,114$26,964,0001.69%
Sterling Global Strategies LLC 22,000$266,0000.98%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,290,024$112,223,0000.98%
MSD Partners, L.P. 965,000$11,657,0000.94%
DOHENY ASSET MANAGEMENT /CA 130,950$1,582,0000.81%
Taylor Wealth Management Partners 128,110$1,548,0000.69%
Bellevue Group AG 318,000$3,841,0000.69%
View complete list of HALOZYME THERAPEUTICS INC shareholders